Long-term efficacy and safety of secukinumab in patients with moderate-to-severe hidradenitis suppurativa: week 104 results from the SUNSHINE and SUNRISE extension trial

塞库金单抗 医学 临床终点 临床试验 安慰剂 耐受性 不利影响 内科学 养生 加药 银屑病性关节炎 疾病 病理 替代医学
作者
Alexa B. Kimball,Falk G. Bechara,Aysha Badat,Evangelos J. Giamarellos‐Bourboulis,Alice B. Gottlieb,Gregor B. E. Jemec,Z. Reguiaï,A. Villani,Ivette Alarcón,Amita Bansal,Francesca Gasperoni,Ruvie Martin,Bertrand Paguet,Lorenz Uhlmann,Hichem Zouater,Shoba Ravichandran,Afsáneh Alavi
出处
期刊:British Journal of Dermatology [Oxford University Press]
卷期号:192 (4): 629-640 被引量:9
标识
DOI:10.1093/bjd/ljae469
摘要

BACKGROUND: The SUNSHINE and SUNRISE phase III trials demonstrated sustained clinical efficacy of secukinumab in patients with moderate-to-severe hidradenitis suppurativa (HS) through 52 weeks. Patients completing the core trials could enter a 4-year extension trial. OBJECTIVES: To evaluate the long-term efficacy, safety/tolerability and maintenance of clinical response to secukinumab through week 104 in the extension trial. METHODS: Patients with a hidradenitis suppurativa (HS) clinical response (HiSCR) at week 52 of the core trials (extension trial baseline visit) entered a randomized withdrawal period. HiSCR responders receiving subcutaneous secukinumab 300 mg every 2 or 4 weeks (SECQ2W/SECQ4W) through week 52 in the core trials were randomized 2 : 1 to continue secukinumab (SECQ2W-R-Q2W or SECQ4W-R-Q4W) or receive placebo (SECQ2W-R-PBO or SECQ4W-R-PBO) through week 104. The primary endpoint was time to loss of response (LOR; newly defined for this trial) through week 104 in week 52 HiSCR responders (SECQ2W-R-Q2W vs. SECQ2W-R-PBO and SECQ4W-R-Q4W vs. SECQ4W-R-PBO). Time to LOR was tested at 1.25% (one-sided) for each comparison (one-sided familywise alpha of 2.5%) through week 104. If LOR was met, patients could remain in the trial on open-label secukinumab treatment. Additional endpoints included safety and HiSCR. The trial was registered with ClinicalTrials.gov (NCT04179175). RESULTS: Overall, 84.3% of patients who completed the core trials entered the extension trial; 55.9% were week 52 HiSCR responders. The primary endpoint was not met for either secukinumab dosing regimen. The estimated risk reduction for LOR was 13% (SECQ2W-R-Q2W vs. SECQ2W-R-PBO; one-sided P = 0.25) and 30% (SECQ4W-R-Q4W vs. SECQ4W-R-PBO; one-sided P = 0.04). The median time to LOR was numerically longer in the secukinumab arms vs. placebo {SECQ2W-R-Q2W [283 days; 95% confidence interval (CI) 176, -] vs. SECQ2W-R-PBO [239 days; 95% CI 120, -]; SECQ4W-R-Q4W [365 days 95% CI 225, -] vs. SECQ4W-R-PBO [171 days; 95% CI 113-337]}. In week 52 HiSCR responders reporting LOR, 44% (SECQ2W-R-Q2W), 58% (SECQ2W-R-PBO), 40% (SECQ4W-R-Q4W) and 34% (SECQ4W-R-PBO) were achieving HiSCR at the time of LOR. Overall, the safety of secukinumab was consistent with the core trials. CONCLUSIONS: The primary endpoint of this trial was not met. HiSCR was maintained in many patients at the time of LOR. The safety of secukinumab was consistent with the previously characterized safety profile in the core trials.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
鳗鱼铭发布了新的文献求助10
刚刚
科目三的应助被枫丶采纳,获得10
刚刚
加速度完成签到,获得积分10
刚刚
RosecLuo完成签到 ,获得积分10
刚刚
帅狗发布了新的文献求助10
1秒前
情怀的应助被芙氟采纳,获得10
1秒前
2秒前
hkp发布了新的文献求助10
3秒前
淳之风完成签到,获得积分10
3秒前
4秒前
5秒前
lll完成签到,获得积分10
6秒前
JamesPei的应助被天蓬猪大帅采纳,获得10
6秒前
Nole的应助被平淡雪瑶采纳,获得10
6秒前
CipherSage的应助被41651653采纳,获得10
6秒前
无花果的应助被轻松的迎曼采纳,获得10
7秒前
ming发布了新的文献求助10
8秒前
8秒前
8秒前
lil完成签到,获得积分10
8秒前
Mr.egg发布了新的文献求助10
8秒前
云与客发布了新的文献求助10
9秒前
LUO111完成签到,获得积分10
9秒前
00hello00发布了新的文献求助10
9秒前
9秒前
FashionBoy的应助被QQ采纳,获得10
10秒前
大院的鸭完成签到,获得积分10
10秒前
科研通AI6.3的应助被zcw采纳,获得10
10秒前
11秒前
搜集达人的应助被水煮鱼采纳,获得10
11秒前
隐形曼青的应助被任伟超采纳,获得10
11秒前
权瑞松发布了新的文献求助30
13秒前
孙昌耀完成签到,获得积分10
13秒前
zhanghang完成签到,获得积分10
13秒前
lll发布了新的文献求助30
14秒前
简简单单完成签到,获得积分10
15秒前
孔原完成签到 ,获得积分20
15秒前
16秒前
程璐完成签到,获得积分10
16秒前
oo发布了新的文献求助10
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8193335
求助须知:如何正确求助?哪些是违规求助? 9579489
关于积分的说明 21865844
捐赠科研通 7792843
什么是DOI,文献DOI怎么找? 3437210
关于科研通互助平台的介绍 2560687
邀请新用户注册赠送积分活动 2483996